ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Archemix, a privately held biotech company based in Cambridge, Mass., added to its growing list of partners this week through deals with Merck Serono and Takeda Pharmaceutical. The alliances underscore growing interest in developing drugs based on aptamers, single-stranded nucleic acids that have binding properties similar to antibodies but are chemically synthesized.
Merck Serono, the prescription drug arm of Germany's Merck, has signed on for a multiyear alliance to develop aptamer-based drugs to treat cancer. As part of the deal, Merck will take a $29.8 million stake in Archemix. Merck retains an option to buy stock in the company if it goes public.
The deal deepens the relationship between the companies, which established a research pact earlier this year to develop cancer treatments. Merck Serono will have access to Archemix' lead-stage aptamer programs in oncology and can choose to develop aptamers against six other targets for cancer and other indications.
In a separate pact, Archemix will get a $6 million payment from Japan's Takeda. The multiyear deal—Archemix' sixth major partnership in the past year—calls for Archemix to come up with aptamer-based product candidates against three targets identified by Takeda, which will own the rights to develop and commercialize those products. Archemix will also receive R&D funding, as well as milestone payments and royalties on sales of any products that come out of the collaboration.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter